mirikizumab · Omvoh

Monoclonal antibody

Also known as LY3074828

Approvedregulatory verdict

Evidence outlook

Approved: Crohn's Disease, Ulcerative Colitis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (6)
CN
  • Adults with moderate to severe active Crohn's disease and ulcerative colitis (IV and SC forms)
Product first approved 2026news.cn
CA
  • Adults with moderately to severely active Crohn's diseasebiospace.com
  • Moderately to severely active ulcerative colitis in adults with inadequate response, loss of response or intolerance to conventional therapy, a biologic or a JAK inhibitor (Notice of Compliance)newswire.ca
Product first approved 2023
EU
  • Moderately to severely active ulcerative colitis in adults
Product first approved 2023EMA
UK
  • Moderately to severely active ulcerative colitis and Crohn's disease
Product first approved 2023medicines.org.uk
JP
  • Moderately to severely active ulcerative colitis (induction and maintenance) where existing therapy is inadequate; Lilly obtained the approval in March 2023
Product first approved 2023answers.and-pro.jp

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (15)
Crohn's Disease
NCT06937099 · Eli Lilly and Company
2025-06-26 – 2028-05 · Crohn's Disease, Obesity or Overweight
What this study did
NCT05509777 · Eli Lilly and Company
2024-03-13 – 2028-04 · Crohn's Disease
What this study did
NCT04232553 · Eli Lilly and Company
2020-06-22 – 2028-03 · Crohn's Disease
What this study did
Ulcerative Colitis
NCT04844606 · Eli Lilly and Company
2021-05-26 – 2030-12 · Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
What this study did
NCT06937086 · Eli Lilly and Company
2025-06-26 – 2028-04 · Ulcerative Colitis, Obesity or Overweight
What this study did
NCT03519945 · Eli Lilly and Company
2018-07-18 – 2027-12 · Ulcerative Colitis
What this study did
NCT05784246 · Eli Lilly and Company
2023-11-22 – 2026-05-01 · Ulcerative Colitis
What this study did
NCT04469062 · Eli Lilly and Company
2021-04-20 – 2024-06-05 · Ulcerative Colitis
What this study did
Other / comorbidity
NCT03556202 · Eli Lilly and Company
2018-09-03 – 2022-02-07 · Psoriasis
What this study did
Phase 2 (6)
Crohn's Disease
NCT02891226 · Eli Lilly and Company
2016-12-14 – 2021-02-05 · Crohn's Disease
What this study did
Ulcerative Colitis
NCT07186101 · Eli Lilly and Company
2025-11-10 – 2029-03 · Ulcerative Colitis
What this study did
NCT06598943 · Eli Lilly and Company
2024-10-10 – 2027-07 · Ulcerative Colitis, Ulcerative Colitis Chronic
What this study did
NCT04004611 · Eli Lilly and Company
2020-05-18 – 2023-03-15 · Ulcerative Colitis
What this study did
NCT02589665 · Eli Lilly and Company
2015-12-09 – 2019-05-07 · Ulcerative Colitis
What this study did
Other / comorbidity
NCT02899988 · Eli Lilly and Company
2016-09-14 – 2019-05-08 · Plaque Psoriasis
What this study did
Phase 1 (18)
Other / comorbidity
NCT07446101 · Eli Lilly and Company
2026-03-24 – 2027-02 · Healthy
What this study did
NCT06475729 · Eli Lilly and Company
2024-06-24 – 2024-12-27 · Healthy
What this study did
NCT05644353 · Eli Lilly and Company
2022-12-05 – 2023-05-25 · Healthy
What this study did
NCT05515601 · Eli Lilly and Company
2022-08-31 – 2023-02-20 · Healthy
What this study did
NCT05069896 · Eli Lilly and Company
2021-10-05 – 2022-06-22 · Healthy
What this study did
NCT04607733 · Eli Lilly and Company
2020-11-02 – 2021-05-17 · Healthy
What this study did
NCT04548219 · Eli Lilly and Company
2020-09-11 – 2021-01-11 · Healthy
What this study did
NCT04137380 · Eli Lilly and Company
2019-12-04 – 2020-12-11 · Healthy
What this study did
NCT03718884 · Eli Lilly and Company
2018-10-23 – 2019-10-28 · Psoriasis
What this study did
NCT03886948 · Eli Lilly and Company
2019-03-27 – 2019-10-04 · Healthy
What this study did
NCT03748940 · Eli Lilly and Company
2018-10-10 – 2019-06-18 · Healthy
What this study did
NCT03662100 · Eli Lilly and Company
2018-09-06 – 2019-01-25 · Healthy
What this study did
NCT02568423 · Eli Lilly and Company
2015-12-02 – 2018-10-24 · Healthy
What this study did
NCT03456713 · Eli Lilly and Company
2018-03-06 – 2018-08-13 · Healthy
What this study did
NCT03053622 · Eli Lilly and Company
2017-04-24 – 2018-04-03 · Healthy
What this study did
NCT03220126 · Eli Lilly and Company
2017-07-17 – 2018-02-23 · Healthy
What this study did
NCT03188510 · Eli Lilly and Company
2017-06-30 – 2017-11-27 · Healthy
What this study did
NCT01947933 · Eli Lilly and Company
2013-10 – 2015-02 · Psoriasis
What this study did
Phase 4 (10)
Crohn's Disease
NCT07782021 · Icahn School of Medicine at Mount Sinai
2026-12 – 2029-07 · Crohn's Disease, Perianal Fistula
What this study did
NCT07659353 · University Hospital Schleswig-Holstein
2026-08-01 – 2029-03-31 · Chrohn's Disease
What this study did
NCT07292012 · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
2026-05-11 – 2028-11 · Crohn Disease (CD)
What this study did
NCT06997965 · Alimentiv Inc.
2026-04-20 – 2028-04-01 · Crohn Disease
What this study did
Ulcerative Colitis
NCT07235904 · University Hospital Schleswig-Holstein
2025-12-05 – 2028-10 · Ulcerative Colitis (UC)
What this study did
NCT07612267 · Eli Lilly and Company
2026-08-05 – 2028-09 · Lactation, Inflammatory Bowel Disease
What this study did
INSIGHT-IBD Pragmatic Studyenrolling by invitation
NCT07686757 · Specialty Networks Research.
2026-08-12 – 2028-06 · Ulcerative Colitis (UC), Crohn Disease (CD)
What this study did
NCT07059130 · Rubix LS
2025-07-16 – 2026-02-28 · Crohn Disease (CD), Crohns Disease, Ulcerative Colitis (UC)
What this study did
NCT06626165 · Showa Inan General Hospital
2024-07-20 – 2025-09-30 · Ulcerative Colitis
What this study did
Other / comorbidity
NCT06864403 · University of North Carolina, Chapel Hill
2025-08-12 – 2027-10 · Pouchitis, Pouches, Ileoanal, Pouch, Ileal
What this study did
Appears in other studies (2)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (2)
Crohn's Disease
NCT07483099 · Eli Lilly and Company
2026-05-04 – 2028-03 · Crohn Disease
What this study did
Ulcerative Colitis
NCT07483073 · Eli Lilly and Company
2026-05-04 – 2028-03 · Colitis, Ulcerative, Crohn Disease
What this study did

Competitive landscape

This mechanism is crowded: 12 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Crohn's Disease: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Mirikizumab (Omvoh): this drugApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT03926130: Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Response at Week 52 (Placebo and Mirikizumab) (Week 12 to Week 52): Placebo 9.0% (95% CI 5.1-13.0) vs Mirikizumab 38.0% (95% CI 34.0-42.0); p=<0.000001 (Placebo vs Mirikizumab)
Adalimumab (Humira)ApprovedMonoclonal antibodyTNF-alphaPartial signal
NCT02499783: Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4 (Week 4): Double-Blind Period, Weeks 0 to 4: Placebo 6.8% vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg 37.3%; p=<0.001 (Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg)
NCT02065570: Percentage of Participants Who Achieved Clinical Remission at Week 4 (Week 4): Induction: Standard Induction Dose 43.7% vs Induction: Higher Induction Dose 43.5%; p=0.939 (Induction: Standard Induction Dose vs Induction: Higher Induction Dose) missed
Adalimumab-Aacf (Idacio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aaty (Yuflyma)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adaz (Hyrimoz)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adbm (Cyltezo)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT02871635: Clinical response (CDAI decrease of 70 points or more) at week 4, BI 695501 vs Humira (modified full analysis set): 61/68 (90%) vs 68/72 (94%); adjusted risk ratio 0.945 (90% CI 0.870 to 1.028), lower limit above the exploratory non-inferiority margin of 0.76 (Hanauer 2021, Lancet Gastroenterol Hepatol).
Adalimumab-Afzb (Abrilada)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aqvh (Yusimry)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Atto (Amjevita)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Bwwd (Hadlima)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Fkjp (Hulio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Ryvk (Simlandi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Budesonide (Entocort EC)ApprovedSmall moleculeGlucocorticoid receptorWeak signalFeatured results are safety only in this race
Budesonide (Ortikos)
ApprovedUS marketing discontinued
—Glucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Certolizumab Pegol (Cimzia)ApprovedAntibody fragmentTNF-alphaWeak signal
NCT00552058: Clinical remission at Week 6: 31.6% (95% CI 25.4-37.8) certolizumab pegol vs 25.4% (95% CI 19.5-31.3) placebo; no p-value reported missed
NCT00297648: Mean Change From Baseline in CDEIS (Crohn's Disease Endoscopic Index of Severity) Score at Week 10 Using Local Non-blinded Assessments (Baseline, Week 10): CDP870 400 mg -6.47 score on a scale (95% CI -7.6 to -5.34)
DexamethasoneApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Guselkumab (Tremfya)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
QUASAR/GALAXI: superior to ustekinumab on pooled endoscopic endpoints
Infliximab (Remicade)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT00094458: Percentage of Participants With Corticosteriod-free Clinical Remission (Week 26): Azathioprine + Placebo 30.0% vs Infliximab + Placebo 44.4% vs Infliximab + Azathioprine 56.8%; p=<0.001 (Azathioprine + Placebo vs Infliximab + Azathioprine), p=0.006 (Azathioprine + Placebo vs Infliximab + Placebo), p=0.022 (Infliximab + Placebo vs Infliximab + Azathioprine)
NCT00269841: Primary end point achieved by 68% (5 mg/kg) and 56% (10 mg/kg) vs 26% on placebo (P=0.002 and P=0.02).
Infliximab-Abda (Renflexis)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Axxq (Avsola)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Dyyb (Inflectra)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT02096861: CDAI-70 response at Week 6: CT-P13 69.4% (77/111) vs originator infliximab 74.3% (81/109); difference -4.9% (95% CI -16.9 to 7.3), above the -20% non-inferiority margin
Infliximab-Dyyb (Zymfentra)ApprovedMonoclonal antibodyTNF-alphaReliable signalNo reviewed efficacy summary in this indication
Infliximab-Qbtx (Ixifi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
MethylprednisoloneApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Natalizumab (Tysabri)ApprovedMonoclonal antibodyα4 integrinPartial signal
NCT00032799: Week 10 clinical response (CDAI decrease >=70): natalizumab 56% vs placebo 49% (P=0.05); remission (CDAI <150): 37% vs 30% (P=0.12) missed
Risankizumab (Skyrizi)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT03104413: US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission (Week 12): Placebo (Induction Period 1) 19.8% (95% CI 14.1-25.5) vs Risankizumab 600mg (Induction Period 1) 42.0% (95% CI 34.9-49.0) vs Risankizumab 1200mg (Induction Period 1) 40.3% (95% CI 33.4-47.3); p=<0.001 (Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1)), p=< 0.001 (Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1))
NCT03105128: US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission (Week 12): Placebo (Period 1) 24.6% (95% CI 18.2-31.0) vs Risankizumab 600mg (Period 1) 45.2% (95% CI 39.9-50.5) vs Risankizumab 1200mg (Period 1) 41.6% (95% CI 36.3-46.8); p=<0.001 (Placebo (Period 1) vs Risankizumab 600mg (Period 1)), p=<0.001 (Placebo (Period 1) vs Risankizumab 1200mg (Period 1))
Tildrakizumab (Ilumya)
Approved(overall)
Monoclonal antibodyIL-23 p19
Reliable signal(overall)
No reviewed efficacy summary in this indication
Upadacitinib (Rinvoq)ApprovedSmall moleculeJAK, JAK1Reliable signal
NCT03345849: Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12 (Week 12): Placebo 29.1% (95% CI 22.4-35.8) vs Upadacitinib 45 mg QD 49.5% (95% CI 44.2-54.8); p=<0.0001 (Placebo vs Upadacitinib 45 mg QD)
NCT03345836: Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12 (Week 12): Part 1 (Double Blind): Placebo 21.1% (95% CI 14.9-27.2) vs Part 1 (Double Blind): Upadacitinib 45 mg 38.9% (95% CI 33.6-44.2); p=<0.0001 (Part 1 (Double Blind): Placebo vs Part 1 (Double Blind): Upadacitinib 45 mg)
Ustekinumab (Stelara)ApprovedMonoclonal antibodyIL-12 p40Reliable signal
NCT01369355: Number of Participants With Clinical Remission at Week 44 (Week 44): Placebo Subcutaneously (SC) 47/131 (35.9%) vs Ustekinumab 90 Milligram (mg) SC Every 12 Weeks (q12w) 63/129 (48.8%) vs Ustekinumab 90 mg SC q8w 68/128 (53.1%); p=0.040 (Placebo Subcutaneously (SC) vs Ustekinumab 90 Milligram (mg) SC Every 12 Weeks (q12w)), p=0.005 (Placebo Subcutaneously (SC) vs Ustekinumab 90 mg SC q8w)
NCT01369342: Number of Participants With Clinical Response at Week 6 (Week 6): Placebo 60/209 (28.7%) vs Ustekinumab 130 mg 108/209 (51.7%) vs Ustekinumab Approximately (~) 6 Milligram Per Kilogram (mg/kg) 116/209 (55.5%); p=< 0.001 (Placebo vs Ustekinumab 130 mg), p=< 0.001 (Placebo vs Ustekinumab Approximately (~) 6 Milligram Per Kilogram (mg/kg))
Ustekinumab-Aauz (Otulfi)Approved—IL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Aekn (Selarsdi)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Auub (Wezlana)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Hmny (Starjemza)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Srlf (Imuldosa)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Stba (Steqeyma)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Ttwe (Pyzchiva)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Vedolizumab (Entyvio)ApprovedMonoclonal antibodyα4β7 integrinPartial signal
NCT02611817: Percentage of Participants Achieving Clinical Remission at Week 52 (Week 52): Maintenance Phase: Induction IV + Placebo 34.3% (95% CI 26.3-43.0) vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC 48.0% (95% CI 42.0-54.1); p=0.008 (Maintenance Phase: Induction IV + Placebo vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC)
NCT03234907: Percentage of Participants With Enhanced Clinical Response in the Induction Phase at Week 10 (Week 10): Induction Phase: Placebo 24.3% (95% CI 14.8-36.0) vs Induction Phase: Vedolizumab 300 mg 19.4% (95% CI 13.3-26.9); p==0.347 (Induction Phase: Placebo vs Induction Phase: Vedolizumab 300 mg) missed
AfimkibartPhase 3Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
DuvakitugPhase 3Monoclonal antibodyTL1APartial signal
NCT05499130: UC cohort, clinical remission at week 14: 36% (450 mg) / 48% (900 mg) vs 20% placebo, placebo-adjusted 16% (p=.050) / 27% (p=.003). CD cohort, endoscopic response: 26.1% (low dose) / 47.8% (high dose) vs 13.0% placebo. P-values are one-sided at a 0.10 significance level.
HS-20137
Phase 3(overall)
Monoclonal antibodyIL-23 p19
not yet graded(overall)
No reviewed efficacy summary in this indication
JNJ-78934804Phase 3CombinationIL-23 p19, TNF-alphanot yet gradedNo reviewed efficacy summary in this indication
QL2106
Phase 3(overall)
Monoclonal antibodyIL-23 p19
not yet graded(overall)
No reviewed efficacy summary in this indication
Remestemcel-L (Ryoncil)Phase 3Cell therapyAllogeneic MSC therapyPartial signalNo reviewed efficacy summary in this indication
TH-SC01Phase 3Cell therapyMesenchymal stem cells (MSC)Weak signalNo reviewed efficacy summary in this indication
Tirzepatide (Zepbound)Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
TulisokibartPhase 3Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
Icotrokinra (Icotyde)Phase 2/3PeptideIL-23 receptornot yet gradedNo reviewed efficacy summary in this indication
AmiselimodPhase 2Small moleculeS1P receptorPartial signal
NCT02378688: Proportion achieving CDAI-100 response at Week 12: amiselimod 0.4mg 19/39 (48.7%) vs placebo 20/37 (54.1%); odds ratio 0.79, 95% CI [0.31, 1.98], not statistically significant. missed
AVB-114Phase 2Cell therapyImplantable cell/biomaterial constructPartial signal
NCT04847739: Combined remission at 9 months: 45.8% (11/24) with AVB-114 vs 8.3% (2/24) with standard of care; difference 38% (95% CI 11 to 60%) (2025-10-29).
Avrukibart
Phase 2(overall)
Monoclonal antibodyIL-23 p19
Partial signal(overall)
No reviewed efficacy summary in this indication
AZD7798Phase 2Monoclonal antibodyCCR9Weak signalFeatured results are safety only in this race
ExoFloPhase 2Cell therapyMSC-derived exosomesWeak signalFeatured results are safety only in this race
Golimumab (Simponi)Phase 2Monoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
MT-201Phase 2Biologic (subtype unspecified)—not yet gradedNo reviewed efficacy summary in this indication
MT-501Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
ObefazimodPhase 2Small moleculemiR-124not yet gradedNo reviewed efficacy summary in this indication
OmilancorPhase 2Small moleculeLANCL2not yet gradedNo reviewed efficacy summary in this indication
ZotemtegrastPhase 2Small moleculeα4β7 integrinnot yet gradedNo reviewed efficacy summary in this indication
EcoActivePhase 1/2Microbiome therapeuticBacteriophage (anti-AIEC)not yet gradedNo reviewed efficacy summary in this indication
Furestem-CDPhase 1/2Cell therapyAllogeneic MSC therapyWeak signalNo reviewed efficacy summary in this indication
ICG318Phase 1/2Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
ALLO-ASCPhase 1Cell therapyAdipose-derived MSC therapyWeak signalNo reviewed efficacy summary in this indication
BDHK-2009Phase 1Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Hemay007Phase 1Small moleculeTNF-alphaWeak signalNo reviewed efficacy summary in this indication
HRS-7085Phase 1Small moleculeNCBP1/NCBP2 (nuclear cap-binding complex)Weak signalNo reviewed efficacy summary in this indication
IPG11406Phase 1Small moleculeEBI2Weak signalFeatured results are safety only in this race
LMT503Phase 1Small moleculeMacrophage polarization / Cellular metabolismnot yet gradedNo reviewed efficacy summary in this indication
OD-07656Phase 1Small moleculeRIPK2Weak signalNo reviewed efficacy summary in this indication

Large race: only the 67 furthest-along competitors are listed; 8 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(14 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Omvoh (mirikizumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (6)
February 2027 (1)
Phase 1HealthyRecruiting
Est. primary completion 2027-02 · NCT07446101 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2Ulcerative ColitisRecruiting
Est. primary completion 2027-05 · NCT07186101 · CT.gov ↗
What to watch
September 2027 (1)
Phase 4Crohn's DiseaseRecruiting
Est. primary completion 2027-09-01 · NCT06997965 · CT.gov ↗
What to watch
October 2027 (1)
Phase 4Pouchitis, Pouches, Ileoanal, Pouch, IlealActive not recruiting
Est. primary completion 2027-10 · NCT06864403 · CT.gov ↗
What to watch
November 2027 (1)
Phase 4Crohn's DiseaseRecruiting
Est. primary completion 2027-11 · NCT07292012 · CT.gov ↗
What to watch
December 2027 (1)
Phase 3Crohn's DiseaseRecruiting
Est. primary completion 2027-12 · NCT05509777 · CT.gov ↗
What to watch
2028 (6)
March 2028 (1)
Phase 4Ulcerative ColitisRecruiting
Est. primary completion 2028-03 · NCT07235904 · CT.gov ↗
What to watch
April 2028 (1)
Phase 3Ulcerative ColitisRecruiting
Est. primary completion 2028-04 · NCT06937086 · CT.gov ↗
What to watch
May 2028 (1)
Phase 3Crohn's DiseaseRecruiting
Est. primary completion 2028-05 · NCT06937099 · CT.gov ↗
What to watch
June 2028 (1)
Phase 4Crohn's DiseaseEnrolling by invitation
Est. primary completion 2028-06 · NCT07686757 · CT.gov ↗
What to watch
September 2028 (1)
Phase 4Crohn's DiseaseRecruiting
Est. primary completion 2028-09 · NCT07612267 · CT.gov ↗
What to watch
December 2028 (1)
Phase 4Crohn's DiseaseNot yet recruiting
Est. primary completion 2028-12 · NCT07782021 · CT.gov ↗
What to watch
2029 (1)
March 2029 (1)
Phase 4Crohn's DiseaseNot yet recruiting
Est. primary completion 2029-03-31 · NCT07659353 · CT.gov ↗
What to watch
2030 (1)
December 2030 (1)
Phase 3Crohn's DiseaseRecruiting
Est. primary completion 2030-12 · NCT04844606 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

19 October 2026Topline resultPhase 3 SHINE-2 of Omvoh met its primary endpoint in pediatric UC
27 October 2025PresentationLUCENT-URGE Phase 3b bowel urgency results
Eli Lilly · Source ↗
27 October 2025ApprovalFDA approves Omvoh single-injection maintenance regimen for UC
US, FDA · Source ↗
15 January 2025ApprovalFDA approves Omvoh for Crohn's disease
US, FDA · Source ↗